Michael Yee has given his Buy rating due to a combination of factors including the recent positive developments regarding Biogen’s Alzheimer’s drug, Leqembi, in the European market. The European ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Europe's medicines watchdog partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Worldcrunch on MSN6h
Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’sThe first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
US regulators approved Leqembi in 2023 and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved the ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
The firm said Biogen partner Eisai’s request for the EMA’s CHMP to reexamine the MAA for lecanemab in amyloid-positive early Alzheimer’s disease has paid off with a positive recommendation that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback